Neuren Pharmaceuticals Limited
NURPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $3 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $3 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -85.3% | 691.3% | -85.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 47.3% | 92.2% | 26.5% | 90.7% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 38.6% | 91% | 16.8% | 89.4% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 53.2% | 69.6% | 33% | 64.7% |
| EPS Diluted | 0.12 | 1.03 | 0.061 | 0.83 |
| % Growth | -88.3% | 1,580.3% | -92.6% | – |
| Operating Cash Flow | $0 | $0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | $0 |